Lyell Immunopharma Inc (LYEL) - Net Assets
Based on the latest financial reports, Lyell Immunopharma Inc (LYEL) has net assets worth $248.20 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($340.05 Million) and total liabilities ($91.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check LYEL financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $248.20 Million |
| % of Total Assets | 72.99% |
| Annual Growth Rate | -7.95% |
| 5-Year Change | -73.31% |
| 10-Year Change | N/A |
| Growth Volatility | 41.19 |
Lyell Immunopharma Inc - Net Assets Trend (2019–2025)
This chart illustrates how Lyell Immunopharma Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Lyell Immunopharma Inc for the complete picture of this company's asset base.
Annual Net Assets for Lyell Immunopharma Inc (2019–2025)
The table below shows the annual net assets of Lyell Immunopharma Inc from 2019 to 2025. For live valuation and market cap data, see Lyell Immunopharma Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $248.20 Million | -35.17% |
| 2024-12-31 | $382.82 Million | -41.55% |
| 2023-12-31 | $654.95 Million | -21.40% |
| 2022-12-31 | $833.25 Million | -10.38% |
| 2021-12-31 | $929.79 Million | +29.42% |
| 2020-12-31 | $718.44 Million | +76.06% |
| 2019-12-31 | $408.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lyell Immunopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 148988300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Comprehensive Income | $242.00K | 0.10% |
| Other Components | $1.87 Billion | 752.42% |
| Total Equity | $248.20 Million | 100.00% |
Lyell Immunopharma Inc Competitors by Market Cap
The table below lists competitors of Lyell Immunopharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Daesang Corp
KO:001680
|
$486.05 Million |
|
Soho House & Co Inc.
NYSE:SHCO
|
$486.07 Million |
|
Shanxi Antai Group Co Ltd
SHG:600408
|
$486.18 Million |
|
Shenzhen Ecobeauty Co Ltd
SHE:000010
|
$486.19 Million |
|
DONGGUAN R.COMMERC. H YC1
F:857
|
$485.89 Million |
|
Community Healthcare Trust Inc
NYSE:CHCT
|
$485.72 Million |
|
enGene Holdings Inc. Common Stock
NASDAQ:ENGN
|
$485.67 Million |
|
Regal Investment Fund
AU:RF1
|
$485.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lyell Immunopharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 382,824,000 to 248,202,000, a change of -134,622,000 (-35.2%).
- Net loss of 274,448,000 reduced equity.
- New share issuances of 50,000,000 increased equity.
- Other comprehensive income decreased equity by 49,000.
- Other factors increased equity by 89,875,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-274.45 Million | -110.57% |
| Share Issuances | $50.00 Million | +20.14% |
| Other Comprehensive Income | $-49.00K | -0.02% |
| Other Changes | $89.88 Million | +36.21% |
| Total Change | $- | -35.17% |
Book Value vs Market Value Analysis
This analysis compares Lyell Immunopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.43x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.63x to 1.43x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $33.10 | $20.83 | x |
| 2020-12-31 | $58.27 | $20.83 | x |
| 2021-12-31 | $76.61 | $20.83 | x |
| 2022-12-31 | $67.45 | $20.83 | x |
| 2023-12-31 | $52.19 | $20.83 | x |
| 2024-12-31 | $29.28 | $20.83 | x |
| 2025-12-31 | $14.52 | $20.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lyell Immunopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -110.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -762355.56%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.37x
- Recent ROE (-110.57%) is below the historical average (-49.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -31.71% | -19692.09% | 0.00x | 1.36x | $-170.18 Million |
| 2020 | -28.46% | -2636.31% | 0.01x | 1.26x | $-276.32 Million |
| 2021 | -26.91% | -2349.47% | 0.01x | 1.21x | $-343.20 Million |
| 2022 | -21.98% | -216.24% | 0.09x | 1.13x | $-266.44 Million |
| 2023 | -35.82% | -180486.15% | 0.00x | 1.15x | $-300.13 Million |
| 2024 | -89.60% | -562285.25% | 0.00x | 1.28x | $-381.28 Million |
| 2025 | -110.57% | -762355.56% | 0.00x | 1.37x | $-299.27 Million |
Industry Comparison
This section compares Lyell Immunopharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lyell Immunopharma Inc (LYEL) | $248.20 Million | -31.71% | 0.37x | $485.93 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in … Read more